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D-4F, an apoA-1 mimetic, decreases airway
hyperresponsiveness, inflammation, and oxidative stress
in a murine model of asthma
S. D. Nandedkar,* D. Weihrauch,† H. Xu,* Y. Shi,* T. Feroah,§ W. Hutchins,§ D. A. Rickaby,**
N. Duzgunes,†† C. A. Hillery,§ K. S. Konduri,1,§ and K. A. Pritchard, Jr.1,2,*
Departments of Pediatric Surgery,* Anesthesiology,† Pediatrics,§ and Medicine,** Medical College of
Wisconsin, Children’s Research Institute, Zablocki Veterans Administration Medical Center, Milwaukee, WI;
and Department of Microbiology,†† University of the Pacific School of Dentistry, San Francisco, CA

Abstract Asthma is characterized by oxidative stress and
inflammation of the airways. Although proinflammatory lipids are involved in asthma, therapies targeting them remain
lacking. Ac-DWFKAFYDKVAEKFKEAFNH2 (4F) is an apolipoprotein (apo)A-I mimetic that has been shown to preferentially bind oxidized lipids and improve HDL function.
The objective of the present study was to determine the effects of 4F on oxidative stress, inflammation, and airway
resistance in an established murine model of asthma. We
show here that ovalbumin (OVA)-sensitization increased airway hyperresponsiveness, eosinophil recruitment, and collagen deposition in lungs of C57BL/6J mice by a mechanism
that could be reduced by 4F. OVA sensitization induced
marked increases in transforming growth factor (TGF)␤-1,
fibroblast specific protein (FSP)-1, anti-T15 autoantibody
staining, and modest increases in 4-hydroxynonenal (4HNE) Michael’s adducts in lungs of OVA-sensitized mice.
4F decreased TGF␤-1, FSP-1, anti-T15 autoantibody, and
4-HNE adducts in the lungs of the OVA-sensitized mice. Eosinophil peroxidase (EPO) activity in bronchial alveolar lavage fluid (BALF), peripheral eosinophil counts, total IgE,
and proinflammatory HDL (p-HDL) were all increased in
OVA-sensitized mice. 4F decreased BALF EPO activity, eosinophil counts, total IgE, and p-HDL in these mice. These
data indicate that 4F reduces pulmonary inflammation and
airway resistance in an experimental murine model of
asthma by decreasing oxidative stress.—Nandedkar, S. D.,
D. Weihrauch, H. Xu, Y. Shi, T. Feroah, W. Hutchins, D. A.
Rickaby, N. Duzgunes, C. A. Hillery, K. S. Konduri, and K. A.
Pritchard, Jr. D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a
murine model of asthma. J. Lipid Res. 2011. 52: 499–508.
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Asthma is one of the most common chronic illnesses in
children and adults, affecting 5–10% of the population in
North America (1). Asthma accounts for the most hospitalizations and missed school and parent workdays with an
estimated cost of $12 billion per year (2). It is characterized by chronic inflammation, airway hyperresponsiveness
(AHR), collagen deposition, and airway remodeling,
which may lead to progressive irreversible lung damage.
Asthma is primarily an inflammatory disease that occurs
after a triggering agent (allergen) induces the release of
histamine and proinflammatory lipids from eosinophils
and mast cells. Oxidative stress is believed to play important roles in the mechanisms by which asthma increases
AHR and inflammation. Indeed, proinflammatory lipids,
such as LTB4, have been shown to attract lymphocytes and
eosinophils to the bronchial epithelium along with their
associated proinflammatory cytokines and lipid mediators
of inflammation to increase AHR (1, 3).
Recent reports suggest that inflammation in asthma
may be influenced by lipoproteins and/or defects in lipo-
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protein; 4-HNE, 4-hydroxynonenal; H and E, hematoxylin and eosin;
MCh, methacholine; Non-Sen, nonsensitized; OVA, ovalbumin; OVASen, OVA-sensitized; ox-PC, oxidized phosphatidylcholine; p-HDL,
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protein metabolism. In 2005, ABCA1, representing the
first step in reverse cholesterol transport, was reported to
be essential for maintaining normal lipid composition, architecture, and airway physiology of the lung (4). In 2009,
genetic deletion of endothelial lipase was shown to increase HDL nearly 2-fold, which was credited with decreasing AHR and pulmonary inflammation in ovalbumin
(OVA)-sensitized mice (5). In 2010, we reported that genetic deletion of apolipoprotein (apo)A-I specifically
increased pulmonary inflammation and AHR without impairing peripheral vascular function (6). Taken together,
these reports suggest that perturbations in usual lipoprotein metabolism may influence experimental asthma.
Further, these reports indicate that apoA-I and HDL play
important and likely specific anti-inflammatory roles in
protecting the lung.
Ample evidence exists to link oxidative stress to airway
disease (7, 8). In 2003, it was suggested that because oxidized LDL increases recruitment of granulocytes, it may
act as an important mediator of bronchial inflammation
(9). Although no relationship was reported to exist between asthma and concentrations of LDL or HDL, patients
with asthma typically have higher concentrations of oxidized LDL and lower concentrations of paraoxonase-1, a
deficiency that is well recognized for increasing HDL oxidation and impairing HDL function (10). More recently,
clinical studies revealed that asthma decreases glutathione
and increases glutathione disulfide in the fluid lining airway epithelium and that this shift in glutathione balance
worsens in individuals with airway obstruction (11). These
reports indicate that lungs of asthmatic subjects experience greater levels of oxidative stress than the lungs in
nonasthmatic subjects and that this increase in oxidative
stress in the lung may promote oxidation of LDL and
HDL. In atherosclerosis, such shifts in oxidative stress are
believed to play important roles in accelerating lesion formation. Interestingly, chronic states of oxidative stress and
inflammation are credited with converting anti-inflammatory HDL into proinflammatory (p)-HDL, which may
even participate in the inflammatory processes (12, 13).
Whether or not the oxidative stress and inflammation associated with asthma increase p-HDL remains unknown.
4F (Ac-DWFKAFYDKVAEKFKEAFNH2) is an amphipathic, a helical peptide that functions as an apoA-I mimetic
(14, 15). Previously, we showed that 4F improved endothelium-dependent vasodilatation in three diverse murine
models of vascular disease: hypercholesterolemia, sickle
cell disease (16), and systemic sclerosis (17). In tight-skin
mice, a murine model of systemic sclerosis, intraperitoneal
4F treatments also reduced the levels of p-HDL (17). As 4F
decreases inflammation and improves vascular function in
such a diverse array of murine models of vascular disease,
we wondered if 4F was capable of inhibiting pulmonary
inflammation and AHR in experimental asthma. To test
this hypothesis, C57BL/6J mice were sensitized to OVA to
induce experimental asthma (18) and then treated intranasally with 4F. Our findings indicate that 4F is a potent
inhibitor of AHR, pulmonary inflammation, and collagen
deposition in lungs of mice with experimental asthma. Ac500
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cordingly, 4F may be useful for limiting the effects of allergen-induced airway disease in asthma.

METHODS
Animals
All protocols using mice were approved by the Institutional
Animal Care and Use Committee (IACUC) of the Medical College of Wisconsin and Zablocki Veterans Administration Medical
Center.

4F
4F was synthesized using all D-amino acids as previously described (19, 20). Scrambled D-4F was synthesized with the same
D-amino acids as D-4F but in a sequence (Ac-DWFAKDYFKKAFVEEFAK-NH2) that does not promote formation of an
a-helix.

Ovalbumin sensitization
On day 0, heat coagulated OVA (Grade II, Sigma Chemical
Co., St Louis, MO,) was inserted subcutaneously on the dorsal
aspect of the cervical region of 6-8 wk old male C57BL/6J mice.
On days 14–24, the mice were exposed to 30 min aerosolization
of an OVA (6%) solution in PBS on alternate days for a period of
10 days as described (18). Thereafter, mice were exposed to aerosolized OVA (6%) twice a week until euthanasia.

4F treatments
Intranasal 4F treatments were initiated on day 25. The experimental test groups were nonsensitized (Non-Sen) mice treated
with PBS (30 µL) or 4F in PBS (20 µg in 30 µL) and OVA-sensitized (OVA-Sen) mice treated with PBS or 4F (20 mg in 30 ml of
PBS) once a day for 4 weeks for initial histology and AHR studies.
At the time of euthanasia, samples were collected from a separate
set of mice for eosinophil peroxidase (EPO) in bronchial alveolar lavage fluid (BALF), lung histology, peripheral blood eosinophils, total IgE, and p-HDL levels as we described before (19, 21).
Scrambled D-4F (20 µg in 30 µL PBS) was used as a peptide control in place of 4F in PBS in OVA-Sen mice compared with OVASen mice treated with PBS alone.

Airway resistance
AHR measurements in response to methacholine (MCh) were
performed on Non-Sen PBS controls (±4F) and OVA-Sen (±4F)
mice. As an antigen challenge and to demonstrate sensitization,
mice were exposed to aerosolized OVA (6%) 24 h before AHR
studies.
To assess AHR, all mice were anesthetized by an intraperitoneal injection of pentobarbital sodium (= [wt (kg) × 90 mg/kg] /
5 mg/ml). Anesthetized mice were placed on a 37°C heating
pad to maintain core body temperature. After confirming anesthesia by absence of pain reflex (paw pinch), mice were tracheostomized and intubated with a 1/2 inch long thin walled metal
tube (0.05 in outside diameter, 0.042 in inside diameter). Mice
were then connected to a computer-controlled small animal ventilator (flexiVent, SCIREQ, Montreal, PQ, Canada) and ventilated at a tidal volume of 9 ml/kg at a frequency of 150 breaths/
min (default ventilation for mice) (22–25). A positive end-expiratory pressure of 3 cmH2O was applied to the breathing circuit by
submerging the outlet of the expiratory line 3 cm below the water surface in an Erlenmeyer flask.
After the mice were instrumented, they were paralyzed with an
intraperitoneal injection of pancuronium bromide (0.04 µg/kg)

to eliminate the possibility of involuntary smooth muscle cell
contraction during airway studies. The position of the mice was
carefully adjusted and assessed with standardized pulmonary tests
until a minimal airway resistance was verified. AHR was assessed
using forced oscillation techniques and Prime-2 perturbations.
Briefly, a Prime-2 perturbation is a forced 2 s pause in ventilation.
The testing protocol for measuring AHR started with two pressure limited total lung capacity maneuvers with an intervening
period of 30 s.
AHR was then assessed by administering a series of progressively increasing concentrations of MCh to induce successive increases in bronchoconstriction (26, 27). Positive end-expiratory
pressure was set at 3 cmH2O. The MCh challenge was performed
at six different concentrations (1.25, 3.125, 6.25, 12.5, 18.0, 25.0
mg/ml dissolved in physiological buffered saline), which was
aerosolized and vented into the anesthetized mouse using an ultrasonic nebulizer (Aeroneb, SCIREQ) connected in-line through
the inspiratory arm of the flexiVent. The aerosolized MCh was
administered for a total of 20 breaths at a tidal volume of ⵑ0.4 ml
at a rate of 30 breaths/min. Immediately following MCh delivery,
the nebulizer was quickly removed from the inspiratory arm of
the flexiVent and default ventilation reinstated. Then for the
next 3 min, a Prime-2 perturbation was repeatedly applied every
20 s.
The pressure and flow data obtained during the application of
each Prime-2 perturbation have been described before (22, 24,
28). Briefly, these data were used to calculate a complex input
impedance of the respiratory system (Zrs). Zrs was then fit to a
model consisting of a single airway serving a constant-phase viscoelastic tissue unit (29). Data analysis yields calculations for RN
(cmH2O•s•ml21), which is Newtonian resistance composed
mostly of flow resistance in conduit airways; G (cmH2O•ml21),
which reflects viscous dissipation of energy in the respiratory
tissues (tissue dampening/resistance); and, H (cmH2O•ml21),
which reflects elastic energy storage in the tissues (tissue
elastance/stiffness). The peak values for RN, G, and H were averaged for each mouse. Raw values for RN, G, and H were expressed
as the mean ± SEM for each experimental test group.

Histopathology
The standard protocol for fixing the lungs was to inflate the
lung with 0.5 ml PBS-Zn-formalin prior to removal. The tissues
were embedded in paraffin, sections cut (5 µm), and stained either with hematoxylin and eosin (H and E) to enhance cytoplasmic and nuclear structures or with McLetchie’s trichrome to
visualize collagen. Images were captured on a Zeiss Imager.Z1
microscope using 40×/0.95 aperture objective and Axiocam HRc
camera and Axiovision Software (version 4.6) (all from Carl Zeiss,
Heidelberg, Germany).

Immunofluorescence studies: effects of OVA
sensitization and 4F treatments on activation of TGF␤-1,
FSP-1 expression, T15 autoantibodies, and 4-HNE
Michael’s adducts in the lung
Immunofluorescence was performed on 5 µm sections of the
fixed lungs. Two sections were mounted on each slide. Sections
were deparaffinized with xylene (three changes) and dehydrated
in a descending alcohol row. The sections were incubated separately with rabbit polyclonal antibodies against transforming
growth factor (TGF)b-1 and fibroblast specific protein (FSP)-1
(1:50 for TGFb-1 and 1:100 for FSP-1; Santa Cruz Biotechnology, Santa Cruz, CA). T15-type autoantibodies against oxidized
phosphatidylcholine [ox-PC, specifically, 1-palmitoyl-2-oxovaleroyl-sn-glycero-3-phosphorylcholine (POVPC)] were detected
with a murine anti-T15 idotype antibody (30, 31); and a rabbit

anti-4-hydroxynonenal (4-HNE) Michaels’s adduct antibody
(Calbiochem-EMD, LaJolla, CA) incubated for 30 min at 37°C.
An Alexa Fluoro 488 goat anti-rabbit antibody (catalog no.
A11008, Invitrogen-Molecular Probes, Eugene, OR) was used to
detect anti-TGFb-1, anti-FSP-1, and anti-4-HNE Michael’s adduct antibodies. The anti-T15 antibody was isolated from peritoneal fluid from mice that were injected with a hybridoma cell
line that was kindly provided by Dr. John Kearney (University of
Alabama at Birmingham, Birmingham, AL). The monoclonal
anti-T15-idiotypic antibody is called AB1-2 and is a mouse IgG1,
which is absolutely specific for both the canonical T15 VH + VL
regions (32). The slides were washed with PBS three times and
then incubated with Alexa Fluoro 488 goat anti-mouse IgGH+L
(catalog no. A11001; Invitrogen-Molecular Probes) for 30 min at
37°C. Negative control slides were sections stained with Alexa
Fluoro 488 goat anti-mouse IgGH+L or Alexa Fluoro 488 goat
anti-rabbit polyclonal antibodies alone (i.e., no primary antibody). Nuclei were counterstained for 3 min at room temperature with TO-PRO-3 iodide (Ex/Em = 642 nm/661 nm,
respectively; catalog no. T3605; Invitrogen-Molecular Probes).
The slides were washed and mounted, and images captured on
a krypton argon laser Nikon Eclipse TE2000U confocal microscope (Melville, NY) using 10×/0.17 aperture objective with the
total magnification of 100 (Ex/Em = 488 nm/580 nm for FITC
and 633 nm/661 nm for TO-PRO-3) and IBM EXC1 software
(Armonk, NY). NIH Image J software was used to calculate fluorescent intensity relative to TO-PRO3 as previously described
(17, 33).

EPO activity in BALF and peripheral blood eosinophils
At the time of euthanasia, the trachea was cannulated with a
ball-tipped 24 gauge needle, lungs lavaged with PBS (0.8 ml),
and samples frozen at 270°C. The samples were later thawed and
assayed for EPO activity as previously described (18). Briefly, substrate solution consisting of 0.1 M Na Citrate, O-phenylenediamine, and H2O2 (3%), at pH 4.5, was mixed with BALF
supernatants 1:1. The reaction mixture was incubated at 37°C
and the reaction was stopped by adding H2SO4 (4N). Horseradish peroxidase was used as a standard. EPO activity (Units) was
quantified by measuring absorbance at 490 nm.
Peripheral blood smears were stained with Wright-Giemsa solution. Percent blood eosinophils were calculated from the number of eosinophils per 100 white blood cells counted under a
high power field (100×).

Total IgE
Total IgE was quantified by ELISA. Briefly, 96-well flat-bottom
polystyrene microplates (Fisher Scientific, Hampton, NH) were
coated with anti-mouse IgE (2 µg/ml, 100 µL/well, 4 h at room
temperature, then 12 h at 4°C; BD Biosciences Pharmingen, San
Diego, CA). After washing with PBS-Tween, the plates were
blocked with 1% BSA (Sigma-Aldrich, St Louis, MO) for 1 h and
the wells washed again. Serially diluted standards and test samples were then added to the plate and incubated for 12 h at 4°C.
Following another set of washes, biotinylated anti-mouse IgE was
added to the well (room temperature, 1 h; BD Biosciences
Pharmingen). Excess biotinylated antibody was removed by washing and the wells were incubated with streptavidin peroxidase
(1 h, room temperature; Sigma-Aldrich). After washing the plate
with PBS (200 µL, 3×), the reaction was started by adding 100
µL/well of O-phenylenediamine-substrate [30 mg OPD in 50 ml
sodium citrate, pH 4.0, with 0.25 ml of H2O2 (3%)]. The reaction
was stopped by addition of H2SO4 (2N, 50 µL/well). Absorbance was read at 490 nm using a Biotek EL312e plate reader
(Winooski, VT).
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Total cholesterol and p-HDL
Total cholesterol was quantified using a cholesterol esterase/
oxidase kit from Wako Chemical, Inc. (Richmond, VA). HDL was
isolated from whole plasma with a solution of dextran-sulfateMgCl2 (10 g/L, 0.5 M; Berkeley HeartLab Inc, Alameda, CA),
which precipitates apoB containing lipoproteins. HDL cholesterol was quantified using an HDL Cholesterol E kit from Wako
Diagnostics. Relative rates of 2’,7’-dichlorofluorescin (DCF) have
been shown to provide a sensitive index of the levels of seeding
molecules of lipid hydroperoxides in isolated HDL (34). An aliquot of 1 mg of HDL cholesterol from the supernatants of the
dextran sulfate precipitate was incubated with CuCl2 (5 mM, final
concentration) for 1 h in a 384-well microtiter plate from MJ Research, Inc. (Waltham, MA). After preincubation, 10 ml of DCF
(0.2 mg/ml) was added to the HDL-Cu2+ mixture in a total volume of 30 ml. DCF fluorescence (Ex 485 nm; Em 530 nm) was
measured at 30 min intervals over the next 2 h on an LJL Biosystem AnalystTM HT (Molecular Devices Corp., Sunnyvale, CA).
Rates of DCF fluorescence (units of fluorescence/min) were calculated and expressed as mean ± SEM.

Statistical analysis
Data are presented as the mean ± SEM. Statistical analysis was
either one-way ANOVA with an appropriate post hoc test for determining levels of significance among means of different groups
or two-way ANOVA with an appropriate post hoc test to determine significance between response curves of the different
groups (* P < 0.05; ** P < 0.025; *** P < 0.01).

RESULTS
Airway hyperresponsiveness
OVA-sensitization markedly increased airway resistance
in response to MCh challenge. Intranasal 4F treatments of
Non-Sen mice decreased airway resistance with respect to
RN, an index of Newtonian resistance, in response to a
MCh compared with normal mice treated with just PBS. In
addition, 4F treatments of OVA-Sen mice reduced airway
resistance for RN at the highest concentration of MCh
compared with the levels for OVA-Sen mice treated with
PBS (Fig. 1A). OVA-Sen mice had increased airway resistance with respect to G, a measure of tissue dampening
(Fig. 1B). The increase in G was significant with respect to
interactions between groups as well as with respect to individual MCh concentrations. Further, 4F treatments reduced G below the levels observed in normal mice treated
with PBS (Fig. 1B). OVA-sensitization markedly increased
H, a measure of tissue elastance (Fig. 1C). The increase in
H was significant with respect to both the dose of MCh as
well as between test groups (Fig. 1C). Throughout the
study, intranasal PBS treatments had little effect on AHR.
Histopathology
OVA-sensitization increased eosinophil and polymorphonuclear neutrophil infiltration in the lungs of the mice
compared with NonSen mice (Fig. 2A) In contrast, 4F
treatments (PBS+D-4F) markedly reduced infiltration of
inflammatory cells (Fig. 2A). OVA-Sen mice had increased
perialveolar and perivascular collagen deposition whereas
4F treatments (PBS+D-4F) reduced collagen deposition to
502
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Fig. 1. Effects of ovalbumin and D-4F on airway hyperresponsiveness to methacholine (MCh) challenge. Line graphs showing that
OVA sensitization increases airway resistance to MCh challenge with
respect to large airways RN, Newtonian resistance (A), tissue damping, G, (B), and tissue elastance, H, (C) and that 4F treatments reduce these measures to baseline. Line graphs for PBS-treated mice
suggest that the PBS in which the D-4F was dissolved did not contribute to airway hyperresponsiveness. (N-PBS, Non-Sen PBS-treated,
n = 11; N-D-4F, Non-Sen D-4F in PBS treated, n = 11; S-PBS, OVA-Sen
PBS-treated, n = 10; S-D-4F, OVA-Sen D-4F-treated, n = 10).

levels that appeared similar to those in Non-Sen PBS control mice (Fig. 2B). These histology data indicate that PBS
treatments alone had little effect on pulmonary inflammation or collagen deposition. To control for the possibility
that 4F reduced inflammation and collagen deposition by
its antioxidant properties associated with composition
(35) rather than its unique biophysical structure, OVASen mice were also treated intranasally with scrambled
D-4F. The images in Fig. 3 show that scrambled D-4F had
no effect on recruitment of inflammatory cells or collagen
deposition in OVA-Sen mice.

Fig. 2. Histology: effects of OVA sensitization and D-4F on pulmonary inflammation and collagen deposition. A: Representative
H and E images of sections of lungs from control, nonsensitized
C57BL/6J mice (upper left) and OVA-sensitized C57BL/6J mice
(lower left). Treatment of OVA-Sen mice with 4F reduced infiltration of inflammatory cells into the lung parenchyma (upper right
panel vs. lower right panel). B: Representative McLetchie’s
trichrome images of sections of lungs isolated from control, nonsensitized C57BL/6J mice (upper right) and OVA-sensitized
C57BL/6J mice (lower right). 4F treatments decreased collagen
deposition in the OVA-Sen mice (upper right panel vs. lower right
panel). These images show that PBS and 4F treatments have little
effect on airway inflammation or collagen deposition in normal
C57BL/6J mice (upper images) (n = 4–6, per condition).

Immunofluorescence studies
To determine how inflammation might contribute to
the mechanisms driving collagen deposition in the lungs of
OVA-Sen mice, we examined sections of lungs for changes
in the activation of TGFb-1, expression of FSP-1, as well as
for the presence of T15-type auto-antibodies against ox-PC
and 4-HNE adducts. TGFb-1 expression and activation are
commonly increased in asthma (36). FSP-1 is expressed on
fibroblasts and cells that are transitioning into fibroblasts
(37). Control mice typically express low levels of TGFb-1
(Fig. 4, first column, top panel). In contrast, OVA-sensitization markedly increases TGFb-1 expression (bright green,
Fig. 4, first column, middle panel) compared with PBS con-

Fig. 3. Histology: effects of scrambled D-4F on pulmonary inflammation and collagen deposition in OVA-sensitized mice. Representative H and E images of sections of lungs from OVA-Sen mice
treated with PBS (upper left) or scrambled D-4F (upper right).
Representative trichrome images of sections of lungs from OVASen mice treated with PBS (lower left) or scrambled D-4F (lower
right). (n = 3, per condition).

trols (Fig. 4, first column, top panel). 4F treatments dramatically reduced TGFb-1 expression in the lungs of the
OVA-Sen mice (Fig. 4, first column, bottom panel) to almost the levels observed in control mice (Fig. 4, first column, top panel). TGFb-1 stimulates collagen production,
promotes the transition of a variety of cells into fibroblast
cells, and increases FSP-1 expression on transitioning cells.
Accordingly, expression patterns of FSP-1 should parallel
TGFb-1 activation. As can be seen, control mice express
low levels of FSP-1 (Fig. 4, second column, top panel).
OVA-sensitized mice express high levels of FSP-1 (Fig. 4,
second column, middle panel) in a pattern that was similar
to the expression pattern for TGFb-1. In contrast, 4F treatments decreased FSP-1 expression in the OVA-Sen mice to
essentially the same levels as in control mice.
Oxidative stress in tissue sections can be assessed immunologically using antibodies that detect well-characterized
antigens, such as ox-PC and 4-HNE adducts. Control mice,
which are not under chronic states of oxidative stress, typically exhibit low to nonexistent levels of T15-type autoantibodies against ox-PC (Fig. 3, third column, top panel).
In contrast, marked increases in T15-type auto-antibodies
against ox-PC were observed in the lungs of the OVA-Sen
mice (bright green, Fig. 4, third column, middle panel). 4F
treatments reduced the levels of T15-type auto-antibodies
in the lungs of the OVA-Sen mice (Fig. 4, third column,
lower panel). Although fluorescent intensity for 4-HNE
Michael’s adducts in the lungs of OVA-sensitized mice was
weak, image analysis revealed OVA-sensitization induced a
modest increase in 4-HNE Michael’s adduct formation,
which was also reduced by 4F treatments. In contrast, fluorescent intensities staining for TGFb-1, FSP-1, or T15-type
autoantibodies were robust in OVA-Sen mice and dramatically decreased in OVA-Sen mice treated with 4F (Fig. 4,
last column, bottom panel) to essentially control levels
(Fig. 4, last column, middle panel). (Negative controls for
the immunofluorescence studies are provided as online
supplemental data.)
EPO activity and peripheral eosinophil counts
OVA-sensitization increased BALF EPO activity more
than 4-fold compared with controls (Fig. 5A). In contrast,
4F treatments reduced BALF EPO activity in OVA-Sen
mice by nearly half of that observed in untreated OVA-Sen
mice (Fig. 5A). These changes paralleled peripheral blood
eosinophil counts. OVA-sensitization increased peripheral
eosinophil counts whereas 4F treatments decreased eosinophil counts in the OVA-Sen mice (Fig. 5B).
Total serum IgE
OVA-sensitization significantly increased total IgE levels
in the mice compared with Non-Sen controls (Fig. 6). 4F
treatments decreased IgE levels in the OVA-sensitized
mice compared with IgE levels in untreated OVA-sensitized mice (Fig. 6).
Total cholesterol, HDL cholesterol, and p-HDL
OVA-sensitization and 4F treatment had no effect on total cholesterol or HDL cholesterol compared with Non-Sen
4F inhibits airway inflammation in experimental asthma
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Fig. 4. Immunofluorescence studies: effects of
OVA sensitization and D-4F on TGFb-1 activation,
FSP-1 expression, T15 autoantibodies, and 4-HNE
Michael’s adducts in the lung. Representative immunofluorescence images for TGFb-1, FSP-1, antiT15-type autoantibodies against ox-PC (POVPC)
and 4-HNE adducts in lungs of controls (PBS), OVAsensitized (OVA) mice, and OVA-sensitized-D-4Ftreated (OVA+4F) mice (n = 4–6, per condition).
Intensity of green fluorescence was quantified using
NIH ImageJ software. Data are expressed in arbitrary units and presented as arbitrary density.

DISCUSSION

striction of large airways (RN) was also reduced. Such
changes in airway physiology are analogous to how 4F
improved endothelium- and endothelial nitric oxide synthase (eNOS)-dependent vasodilatation in hypercholesterolemic mice, sickle cell anemia mice (16), and tight-skin
mice (17). These relative changes in airway mechanics
provide additional insight into the pathogenic mechanisms
taking place in OVA-Sen mice treated with and without 4F.

Although many recognize that HDL, and by extension
apoA-I, plays an important anti-atherogenic role in coronary heart disease, logically it should also protect the vascular beds of other organs. We recently reported that
apoA-I plays several important roles in protecting the lung
(6). Genetic deletion of apoA-I increased AHR with respect to tissue dampening and elastance. These changes
coincided with a marked increase in oxidative modification of tissue tyrosines, infiltration of inflammatory cells,
and collagen deposition in the lung (6). Additional studies showed that genetic deletion of apoA-I not only increased oxidative modification of HDL but also decreased
paraoxonase activity without decreasing expression (6).
In the present study, we determined the effects of 4F on
airway physiology in the asthmatic mice employing the
same analytical techniques used in our previous study in
apoA-I knockout mice (6). Studies here showed that OVAsensitization markedly increased airway resistance with respect to RN, G, and H and that intranasal 4F treatments
reduced AHR in OVA-Sen mice. Improvements in airway
responses were most notable with respect to tissue dampening (G) and elastance (H) even though bronchocon-

Fig. 5. Bronchial alveolar lavage fluid (BALF) EPO activity and
peripheral blood eosinophil counts. A: BALF isolated from OVAsensitized mice has higher EPO activity than controls and OVAsensitized-D-4F-treated mice (n = 4–6, per condition). B: Similar
data were observed for % eosinophils calculated from manual cell
counts in peripheral blood smears (n = 4–6, per condition).

controls (Fig. 7A and B, respectively). In contrast, p-HDL
was increased in the OVA-Sen mice compared with NonSen mice (Fig. 7). 4F treatments significantly decreased
p-HDL in OVA-Sen mice compared with untreated OVASen mice (Fig. 7C).
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Fig. 6. Total IgE. ELISA measurements of total plasma IgE reveals that IgE levels were increased in OVA-sensitized mice (n = 11)
compared with controls (n = 4) and OVA-sensitized-D-4F-treated
mice (n = 4).

For example, increased collagen deposition in the perialveolar and perivascular regions of the lung is well recognized for creating stiffer lungs, which increases airway
resistance with respect to tissue dampening and elastance.
Trichrome staining confirms that OVA-sensitization and
chronic exposure to aerosolized OVA not only increases
collagen deposition in the lung but also that intranasal
4F treatments decrease collagen deposition in OVA-Sen
mice.
To examine potential mechanisms driving collagen deposition in OVA-Sen mice, sections of lung were immunostained for TGFb-1, FSP-1, anti-T15 autoantibodies, and
4-HNE adducts. TGFb-1 stimulates collagen production as
well as epithelial and endothelial mesenchymal transition
into fibroblasts (38, 39). FSP-1 is a well-recognized biomarker for fibroblasts and cells that are transitioning into
fibroblasts (40). AB1-2 has an absolute requirement for
the canonical VH and VL regions of T15-type antibodies,

such as EO6 (32), which have been shown to bind POVPC
among various other ox-PC phospholipids (41). 4-HNE, a
highly reactive breakdown product of lipid peroxidation,
reacts with thiols, histidines, and lysines. When 4-HNE
reacts with the free amine of lysine, it forms a covalent
heterocyclic ring that is easily detected using standard immunofluorescence techniques (42). Although immunostaining for anti-T15 type antibodies and 4-HNE adducts
may be an indirect means of quantifying oxidized phospholipids or 4-HNE in tissues, relative changes and patterns of staining provide important insight into which
tissues and cells are experiencing marked increases in oxidative stress.
For example, in OVA-Sen mice, intense TGFb-1 activation can be seen in the perialveolar and perivascular regions immediately adjacent to the airways and blood vessels
but not immediately below or on epithelial and endothelial cells. Although the expression of FSP-1 is greatest in
these same regions, it is also moderately increased throughout the parenchyma. In contrast to the pattern of TGFb-1
activation, FSP-1 is expressed on epithelial cells and endothelial cells. This pattern of FSP-1 expression suggests
that the mechanisms driving mesenchymal transition and
collagen deposition extend beyond the actual site of
TGFb-1 activation. In contrast to patterns for TGFb-1 and
FSP-1, OVA-sensitization dramatically increased anti-T15
antibodies throughout the lung. Nearly every structure
and cell type is positive for anti-T15 antibodies demonstrating that OVA-sensitization induced a dramatic increase in oxidative stress throughout the lung. Control
immunofluoresence studies indicate that this marked increase in anti-T15 antibody staining is not a result of nonspecific IgG accumulation in the lung. Immunofluorescent
staining for 4-HNE adducts shows that the increase in
4-HNE adducts in OVA-Sen mice occurs not only throughout the parenchyma but also on the surface of the epithelium and endothelium and in some regions, in a punctate

Fig. 7. Total cholesterol, HDL cholesterol, and proinflammatory HDL. A: This bar graph shows the concentration of total cholesterol in control, OVA-Sen, and OVA-Sen+D-4F-treated mice (NS = not significant).
B: This bar graph shows HDL cholesterol concentrations in control, OVA-Sen, and OVA-Sen+D-4F-treated
mice. C: Proinflammatory HDL (p-HDL) is a cell-free assay that assesses the oxidizability of HDL. This bar
graph shows that HDL in OVA-sensitized mice is more easily oxidized than HDL isolated from control mice
and that intranasal D-4F treatments decrease HDL oxidizability in OVA-sensitized mice. (NS, not significant;
Controls, n = 4; OVA-sensitized, n = 11; OVA-sensitized+D-4F, n = 4).
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pattern. This makes sense when one considers the fact that
lipid peroxidation increases production of 4-HNE and
that during inflammation hot spots of oxidation are fully
capable of increasing 4-HNE to very high local concentrations (43). In this context, it is important to note that 4F
treatments not only reduced the intensity of immunostaining for each analyte but also ablated these distinct patterns
of activation, expression, innate immune reaction, and/or
adduct formation. These data are consistent with the notion that allergen-induced experimental asthma increases
oxidative stress and activates TGFb-1, which promotes
transition of epithelial and endothelial cells into myofibroblasts, which in turn increases collagen deposition. At the
very least, our observations show that 4F decreases oxidative stress and TGFb-1 activation in OVA-Sen mice and by
extension that this increase in oxidative stress activates
TGFb-1 by an as yet undefined mechanism. Additional
studies are required to determine how OVA-sensitization
increases oxidative stress and how an increase in oxidative
stress activates TGFb-1. More importantly, additional studies are required to determine the exact mechanisms by
which 4F disrupts this process to inhibit collagen deposition in the asthmatic lung.
An increase in total IgE is indicative of active allergeninduced asthma (44). IgE is expressed by B-cells under the
direction of TH2 cells in subjects with atopy (45). In subjects who do not have atopy, the relationship between total
IgE and asthma is less clear. Regardless, IgE is believed to
accelerate asthma by binding to mast cells and basophils
which, in turn, degranulate, release histamine, and generate cytokines that exacerbate pulmonary inflammation. In
this context, it is important to note that 4F significantly
decreased total IgE in the OVA-Sen mice. These data provide further support for the idea that targeting oxidative
stress is an important therapeutic avenue for limiting inflammation in asthma.
Our plasma lipid data confirm that asthma does not alter total plasma cholesterol or HDL concentrations but
significantly increases p-HDL. These original observations
support our hypothesis that asthma increases oxidative
stress such that it markedly increases the oxidizability of
HDL. Under these conditions, the ability of HDL to perform its normal anti-inflammatory and protective functions is likely impaired.
The exact mechanisms by which 4F inhibits experimental asthma remain unknown. What we showed here was
that 4F reduces oxidative stress in the lungs and plasma of
the OVA-Sen mice. 4F may reduce oxidative stress in the
asthmatic lung by binding oxidized lipids, remodeling
HDL, and improving HDL function. A recent report provides strong biophysical evidence that 4F has a much
higher affinity for oxidized lipids and phospholipids than
native lipids (46). Preferentially removing oxidized lipids
from HDL should protect HDL from oxidative modification as well as HDL-associated paraoxonase from inactivation (13, 47). Thus, anything that reduces the potential for
oxidation or protects paraoxonase activity would be anticipated to improve any of HDL’s many functions: increasing
reverse cholesterol transport (48), binding and removal of
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oxidative enzymes from inflamed tissues (19), stimulating
pulmonary •NO production (6), inhibiting vascular O2•⎯
generation (49) and inhibiting LDL-induced increases in
monocyte/leukocyte chemotactic activity (9, 50).
Another way 4F may reduce oxidative stress in experimental asthma is by binding to and stabilizing ABCA1
(51). Stabilization of ABCA1 not only facilitates the transfer of native cholesterol and phospholipid but also their
oxidized counterparts, which logically should also help
protect the lung (52). Alternatively, 4F stabilization of
ABCA1 may also activate the JAK2/STAT3 anti-inflammatory pathway to inhibit cytokine expression as was recently
shown for apoA-I (53) but not for 4F (51, 53). Recent reports indicate that transgenic overexpression of eNOS reduced many of the hallmark features of OVA-induced
asthma in mice (54). Earlier, we showed that 4F restored
•⎯
•NO and O2 balance in LDL-treated endothelial cell cultures by increasing heat shock protein 90 association with
eNOS (55), a protein-protein interaction that is well recognized for enhancing •NO production and decreasing
•⎯
O2 generation from eNOS (56–58). Further, we showed
that 22-hydroxycholesterol dramatically impaired •NO
•⎯
production and increased O2 generation, collagen synthesis, and ABCA1 expression in endothelial cell cultures
(19). Interestingly, adding 4F to these cultures also re•⎯
stored •NO production, decreased O2 generation, and
inhibited collagen synthesis but not ABCA1 expression,
which remained increased (19). Thus, 4F may decrease inflammation in the asthmatic lung by restoring •NO and
O2•⎯ balance via recoupling eNOS. Accordingly, any therapy targeting eNOS-dependent •NO production may attenuate oxidative stress, inflammation, and even collagen
deposition in experimental asthma.
Previously, we showed that 4F improved vasodilatation
but could not reduce vessel wall thickness or decrease
2/2
2/2
mice fed a Western diet (19).
p-HDL in Ldlr /apoA-I
As 4F is fully capable of reducing vessel wall thickness in
2/2
mice, which express apoA-I, we reacholesterol-fed Ldlr
soned that the absence of apoA-I prevented or at least
limited 4F from inhibiting the mechanisms by which hypercholesterolemia impairs vasodilatation and increases
vessel wall thickness in these mice. With respect to experimental asthma, our recent report showing that genetic
loss of apoA-I also increases pulmonary inflammation, collagen deposition, and AHR in Non-Sen mice suggests that
apoA-I is important for preventing pulmonary inflammation and that 4F may inhibit experimental asthma by an
HDL-dependent mechanism.
In conclusion, experimental asthma increases oxidative
stress, pulmonary inflammation, and AHR in mice by
mechanisms that can be attenuated by 4F, an apoA-I mimetic. Oxidative stress likely plays a central role in the
mechanisms by which experimental asthma increases inflammation. Intranasal 4F reduces at least two well-established biomarkers of oxidative stress, decreases recruitment
of inflammatory cells, and prevents collagen deposition,
which reduces pulmonary stiffness and decreases AHR in
experimental asthma. In contrast, scrambled 4F has no effect on recruitment of inflammatory cells or collagen de-

position in OVA-Sen mice. Thus, the mechanisms by which
4F reduces pulmonary inflammation and collagen deposition in experimental asthma is intimately linked to 4F’s
unique amphipathic structure rather than composition.
Additional studies are required to determine the exact
mechanisms by which 4F reduces pulmonary inflammation and AHR in experimental asthma.
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